Immtech gets generic name for DB289
US firm Immtech International says that the US Adopted Names Council (USAN) and the World Health Organization have approved the generic name pafuramidine maleate for the company's oral drug candidate, DB289.
Immtech has an exclusive, worldwide license to pafuramidine and is currently involved in late stage human clinical trials of the drug for the treatment of malaria, Pneumocystis pneumonia and African sleeping sickness.
Rick Sorkin, chief executive of Immtech, said: "we are pleased to be advancing our first oral drug candidate towards regulatory approval and commercial launch. We believe pafuramidine will be an important advancement in the treatment and prevention of infectious diseases. With its unique mechanisms of action, pafuramidine represents new hope for patients worldwide."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze